Literature DB >> 29175981

Validation of Noninvasive Tracer Kinetic Analysis of 18F-Florbetaben PET Using a Dual-Time-Window Acquisition Protocol.

Santiago Bullich1, Henryk Barthel2, Norman Koglin3, Georg A Becker2, Susan De Santi4, Aleksandar Jovalekic3, Andrew W Stephens3, Osama Sabri2.   

Abstract

Accurate amyloid PET quantification is necessary for monitoring amyloid-β accumulation and response to therapy. Currently, most of the studies are analyzed using the static SUV ratio (SUVR) approach because of its simplicity. However, this approach may be influenced by changes in cerebral blood flow (CBF) or radiotracer clearance. Full tracer kinetic models require arterial blood sampling and dynamic image acquisition. The objectives of this work were, first, to validate a noninvasive kinetic modeling approach for 18F-florbetaben PET using an acquisition protocol with the best compromise between quantification accuracy and simplicity and, second, to assess the impact of CBF changes and radiotracer clearance on SUVRs and noninvasive kinetic modeling data in 18F-florbetaben PET.
Methods: Using data from 20 subjects (10 patients with probable Alzheimer dementia and 10 healthy volunteers), the nondisplaceable binding potential (BPND) obtained from the full kinetic analysis was compared with the SUVR and with noninvasive tracer kinetic methods (simplified reference tissue model and multilinear reference tissue model 2). Various approaches using shortened or interrupted acquisitions were compared with the results of the full acquisition (0-140 min). Simulations were performed to assess the effect of CBF and radiotracer clearance changes on SUVRs and noninvasive kinetic modeling outputs.
Results: An acquisition protocol using time windows of 0-30 and 120-140 min with appropriate interpolation of the missing time points provided the best compromise between patient comfort and quantification accuracy. Excellent agreement was found between BPND obtained using the full protocol and BPND obtained using the dual-window protocol (for multilinear reference tissue model 2, BPND [dual-window] = 0.01 + 1.00·BPND [full], R2 = 0.97; for simplified reference tissue model, BPND [dual-window] = 0.05 + 0.92·BPND [full], R2 = 0.93). Simulations showed a limited impact of CBF and radiotracer clearance changes on multilinear reference tissue model parameters and SUVR.
Conclusion: This study demonstrated accurate noninvasive kinetic modeling of 18F-florbetaben PET data using a dual-window acquisition, thus providing a good compromise between quantification accuracy, scan duration, and patient burden. The influence of CBF and radiotracer clearance changes on amyloid-β load estimates was small. For most clinical research applications, the SUVR approach is appropriate. However, for longitudinal studies in which maximum quantification accuracy is desired, this noninvasive dual-window acquisition with kinetic analysis is recommended.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  amyloid-beta; cerebral blood flow; florbetaben PET; quantification

Mesh:

Substances:

Year:  2017        PMID: 29175981     DOI: 10.2967/jnumed.117.200964

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  12 in total

1.  The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community.

Authors:  Valentina Garibotto; Nathalie L Albert; Henryk Barthel; Bart van Berckel; Ronald Boellaard; Matthias Brendel; Diego Cecchin; Ozgul Ekmekcioglu; Elsmarieke van de Giessen; Eric Guedj; Adriaan A Lammerstma; Franck Semah; Tatjana Traub-Weidinger; Donatienne Van Weehaeghe; Silvia Morbelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-17       Impact factor: 9.236

2.  Exploiting the Full Potential of β-Amyloid and Tau PET Imaging for Drug Efficacy Testing.

Authors:  Henryk Barthel; John Seibyl; Adriaan A Lammertsma; Victor L Villemagne; Osama Sabri
Journal:  J Nucl Med       Date:  2020-05-15       Impact factor: 10.057

3.  Correlation of Early-Phase F-18 Florapronal PET with F-18 FDG PET in Alzheimer's Disease and Normal Brain.

Authors:  Jieun Jeong; Young Jin Jeong; Kyung Won Park; Do-Young Kang
Journal:  Nucl Med Mol Imaging       Date:  2019-09-11

4.  Early detection of amyloid load using 18F-florbetaben PET.

Authors:  Santiago Bullich; Núria Roé-Vellvé; Marta Marquié; Susan M Landau; Henryk Barthel; Victor L Villemagne; Ángela Sanabria; Juan Pablo Tartari; Oscar Sotolongo-Grau; Vincent Doré; Norman Koglin; Andre Müller; Audrey Perrotin; Aleksandar Jovalekic; Susan De Santi; Lluís Tárraga; Andrew W Stephens; Christopher C Rowe; Osama Sabri; John P Seibyl; Mercè Boada
Journal:  Alzheimers Res Ther       Date:  2021-03-27       Impact factor: 6.982

5.  Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-study.

Authors:  Santiago Bullich; Andre Mueller; Susan De Santi; Norman Koglin; Stephen Krause; June Kaplow; Michio Kanekiyo; Núria Roé-Vellvé; Audrey Perrotin; Aleksandar Jovalekic; David Scott; Michelle Gee; Andrew Stephens; Michael Irizarry
Journal:  Alzheimers Res Ther       Date:  2022-07-27       Impact factor: 8.823

6.  β-Amyloid accumulation in the human brain after one night of sleep deprivation.

Authors:  Ehsan Shokri-Kojori; Gene-Jack Wang; Corinde E Wiers; Sukru B Demiral; Min Guo; Sung Won Kim; Elsa Lindgren; Veronica Ramirez; Amna Zehra; Clara Freeman; Gregg Miller; Peter Manza; Tansha Srivastava; Susan De Santi; Dardo Tomasi; Helene Benveniste; Nora D Volkow
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-09       Impact factor: 11.205

7.  Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASL-MRI: proof of concept.

Authors:  Catherine J Scott; Jieqing Jiao; Andrew Melbourne; Ninon Burgos; David M Cash; Enrico De Vita; Pawel J Markiewicz; Antoinette O'Connor; David L Thomas; Philip Sj Weston; Jonathan M Schott; Brian F Hutton; Sébastien Ourselin
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-05       Impact factor: 6.200

8.  Simulating the effect of cerebral blood flow changes on regional quantification of [18F]flutemetamol and [18F]florbetaben studies.

Authors:  Fiona Heeman; Maqsood Yaqub; Isadora Lopes Alves; Kerstin Heurling; Santiago Bullich; Juan D Gispert; Ronald Boellaard; Adriaan A Lammertsma
Journal:  J Cereb Blood Flow Metab       Date:  2020-04-11       Impact factor: 6.200

9.  A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [18F]MK-6240.

Authors:  Ronald Boellaard; Michel Koole; Guilherme D Kolinger; David Vállez García; Talakad G Lohith; Eric D Hostetler; Cyrille Sur; Arie Struyk
Journal:  EJNMMI Res       Date:  2021-05-27       Impact factor: 3.138

Review 10.  The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders.

Authors:  Adam J Schwarz
Journal:  Neurotherapeutics       Date:  2021-04-12       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.